Sanofi SA has a consensus price target of $61 based on the ratings of 7 analysts. The high is $65 issued by Goldman Sachs on March 21, 2025. The low is $58 issued by Morgan Stanley on September 8, 2025. The 3 most-recent analyst ratings were released by Morgan Stanley, Goldman Sachs, and Argus Research on September 8, 2025, March 21, 2025, and July 26, 2024, respectively. With an average price target of $61 between Morgan Stanley, Goldman Sachs, and Argus Research, there's an implied 28.84% upside for Sanofi SA from these most-recent analyst ratings.
1calculated from analyst ratings
| Get Alert | |||||
|---|---|---|---|---|---|
| Dec 9, 2025 | — | — | Previous Buy Current Neutral | Get Alert | |
| Dec 8, 2025 | — | — | Previous Overweight Current Neutral | Get Alert | |
| Oct 27, 2025 | — | — | — | Previous Current Buy | Get Alert |
| Sep 8, 2025 | 22.51% | 5658 | Previous Equal-Weight Current Overweight | Get Alert | |
| Sep 2, 2025 | — | — | Previous Hold Current Buy | Get Alert | |
| Aug 8, 2025 | — | — | Previous Neutral Current Overweight | Get Alert | |
| Mar 21, 2025 | 37.29% | 65 | Previous Initiates Current Neutral | Get Alert | |
| Jul 26, 2024 | 26.73% | 5560 | Previous Buy Current Buy | Get Alert | |
| Jan 23, 2024 | 16.17% | 55 | Previous Initiates Current Equal-Weight | Get Alert | |
| Mar 27, 2023 | 26.73% | 5560 | Previous Current Buy | Get Alert |
The latest price target for Sanofi (NASDAQ:SNY) was reported by Guggenheim on December 9, 2025. The analyst firm set a price target for $0.00 expecting SNY to fall to within 12 months (a possible -100.00% downside). 7 analyst firms have reported ratings in the last year.
The latest analyst rating for Sanofi (NASDAQ:SNY) was provided by Guggenheim, and Sanofi downgraded their neutral rating.
The last upgrade for Sanofi SA happened on September 8, 2025 when Morgan Stanley raised their price target to $58. Morgan Stanley previously had an equal-weight for Sanofi SA.
The last downgrade for Sanofi SA happened on December 9, 2025 when Guggenheim changed their price target from N/A to N/A for Sanofi SA.
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Sanofi, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Sanofi was filed on December 9, 2025 so you should expect the next rating to be made available sometime around December 9, 2026.
While ratings are subjective and will change, the latest Sanofi (SNY) rating was a downgraded with a price target of $0.00 to $0.00. The current price Sanofi (SNY) is trading at is $47.35, which is out of the analyst’s predicted range.
Browse analyst ratings and price targets on all stocks.
A newsletter built for market enthusiasts by market enthusiasts. Top stories, top movers, and trade ideas delivered to your inbox every weekday before and after the market closes.